Progress in neuro-psychopharmacology & biological psychiatrySep 5, 2026

Possible use of 5-HT7 receptor blockers in treating depression from drug and bioengineering viewpoints

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 6, 2026

Abstract

The 5-hydroxytryptamine 7 receptor (5-HT7R) is associated with mood and may be targeted for depression treatment.

Targeting serotonergic receptors could be a relevant approach for treating depression.
5-HT7R is linked to mood, circadian rhythm, and cognition.
Antagonists of the 5-HT7R may have potential therapeutic effects in depression.
The discussion includes both pharmacological and bioengineering strategies for 5-HT7R antagonists.

Simplified

Targeting serotonergic receptors, as well as the serotonin uptake, is a relevant treatment approach for the treatment of depression. The 5-hydroxytryptamine 7 receptor (5-HT₇R) is a G-protein coupled receptor belonging to the serotonergic receptor family, which has received a lot of attention due to its association with mood, circadian rhythm, and cognition. This review discusses the potential of 5-HT₇R antagonists to treat depression, especially focusing on the pharmacological and bioengineering approaches.

Full Text

Full text is available at the source.

View Full Text ↗

Possible use of 5-HT7 receptor blockers in treating depression from drug and bioengineering viewpoints

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the circadian biology brief